Content by Keyword: Mental Disability/Illness

  • print
  • email
  • twitter
  • compact
Report page
B. Defining Utilization

Access and Utilization of New Antidepressant and Antipsychotic Medications. B. Defining Utilization

Utilization is defined as the use of a health care service, procedure, device, or pharmaceutical. Utilization is influenced by access, although the actual utilization of a given pharmaceutical may not reach the maximum level expected given a specified level of "access." Utilization can be recorded in a number of ways: per capita, hospital length o
Report page
A. Defining Access

Access and Utilization of New Antidepressant and Antipsychotic Medications. A. Defining Access

Simply stated, "Access" to a particular health care service may be defined as the set of factors that affect the  potential  ability of an individual or a group to acquire timely and appropriate use of that service. Traditionally, access to health care services has been limited by race, gender, age, and class. 7  These factors cannot be control
Report page
Chapter III. Defining Access and Utilization

Access and Utilization of New Antidepressant and Antipsychotic Medications. Chapter III. Defining Access and Utilization

The United States Department of Health and Human Services charged The Lewin Group with the task of elucidating the mechanisms that affect the extent to which Americans receive the most up-to-date pharmacotherapies for the treatment of mental illness. In examining this problem, we determined that this question is made up of two separate components
Report page
D. Cost-Effectiveness of Newer Antidepressant and

Access and Utilization of New Antidepressant and Antipsychotic Medications. D. Cost-Effectiveness of Newer Antidepressant and Antipsychotic Medications

  ​
Report page
C. Utilization of Newer Antidepressant and

Access and Utilization of New Antidepressant and Antipsychotic Medications. C. Utilization of Newer Antidepressant and Antipsychotic Medications by State Medicaid Programs 1995-1998

New generation antipsychotics and antidepressants have been accepted into common use within Medicaid programs.
Report page
B. Utilization of Antidepressant and

Access and Utilization of New Antidepressant and Antipsychotic Medications. B. Utilization of Antidepressant and Antipsychotic Medications

   
Report page
A. Access to Newer Antidepreseant and

Access and Utilization of New Antidepressant and Antipsychotic Medications. A. Access to Newer Antidepreseant and Antipsychotic Medications

Report page
Chapter II. Principal Findings

Access and Utilization of New Antidepressant and Antipsychotic Medications. Chapter II. Principal Findings

As discussed in the introduction, the present study was guided by three principal questions about the status of pharmaceutical benefits for psychotherapeutic medications. We consider each of these questions in turn. What are the formal policies and procedures implemented by health care payers that affect consumer access to and utilization of ps
Report page
E. Organization of the Report

Access and Utilization of New Antidepressant and Antipsychotic Medications. E. Organization of the Report

Following this introduction, Chapter II summarizes the principal findings of the study. Chapter III provides a detailed discussion of the distinctions between the concepts of "access" and "utilization" that underlie the entire report. Chapters IV and V detail the findings of the primary research interviews investigating the state of access to and
Report page
D. Methodology

Access and Utilization of New Antidepressant and Antipsychotic Medications. D. Methodology

The present analysis was developed based on published literature, pharmaceutical claims, and primary research with stakeholders. It focuses on antidepressants and antipsychotics as general classes of pharmacotherapy, with emphasis on agents introduced to the US market after 1988. Chapters III -- V rely primarily on published literature and primary
Report page
C. Scope of Study

Access and Utilization of New Antidepressant and Antipsychotic Medications. C. Scope of Study

From its outset, this study was designed to answer the above questions by evaluating six principal issues that work together to influence the degree to which consumers have access to and are able to use the most up to date pharmaceutical therapies for mental illnesses. Broadly speaking, these issues include:
Report page
B. Purpose of Study

Access and Utilization of New Antidepressant and Antipsychotic Medications. B. Purpose of Study

The Assistant Secretary for Planning and Evaluation (ASPE), United States Department of Health and Human Services and the National Institute of Mental Health (NIMH) commissioned the present study to identify, document, and assess the factors that affect access to and utilization of new generation antidepressant and antipsychotic medications. Three
Report page
A. Understanding of the Problem

Access and Utilization of New Antidepressant and Antipsychotic Medications. A. Understanding of the Problem

Drug benefits are the fastest growing major cost component both of private insurance and Medicaid, averaging 12.2% growth per year compared to 5.1% for total health spending (1993-1998). 1  In 1997, $78.9 billion were spent on prescription drugs, representing 7% of total health care expenditures. 2  More specifically, spending on the newer antid
Report page
Chapter I: Introduction

Access and Utilization of New Antidepressant and Antipsychotic Medications. Chapter I: Introduction

Report
Access and Utilization of New Antidepressant and

Access and Utilization of New Antidepressant and Antipsychotic Medications

By: The Lewin Group Submitted to:   The Office of the Assistant Secretary for Planning and Evaluation  and The National Institute of Mental Health, U.S. Department of Health and Human Services
Basic report
Psychiatric Boarding Interview Summary

Psychiatric Boarding Interview Summary

U.S. Department of Health and Human Services Psychiatric Boarding Interview Summary David Bender, Nalini Pande and Michael Ludwig The Lewin Group January 9, 2009 PDF Version: http://aspe.hhs.gov/daltcp/reports/2009/PsyBdInt.pdf (20 PDF pages)
  • PsyBdInt.pdf
    export-csvPDF
Basic report
Public Financing of Home and Community Services

Public Financing of Home and Community Services for Children and Youth with Serious Emotional Disturbances: Selected State Strategies

U.S. Department of Health and Human Services Public Financing of Home and Community Services for Children and Youth with Serious Emotional Disturbances: Selected State Strategies Henry T. Ireys, Sheila Pires and Meridith Lee Mathematica Policy Research, Inc. June 2006 PDF Version
  • youthSED.pdf
    export-csvPDF
Basic report
Persons with Severe Mental Illness: How Do They

Persons with Severe Mental Illness: How Do They Fit Into Long-Term Care?

U.S. Department of Health and Human Services Persons with Severe Mental Illness: How Do They Fit Into Long-Term Care Crystal Kuntz Office of the Assistant Secretary for Planning and EvaluationU.S. Department of Health and Human Services May 5, 1995 PDF Version (38 PDF pages)
  • mentalil.pdf
    export-csvPDF
Basic report
Population Estimates of Disability and Long-Term

Population Estimates of Disability and Long-Term Care

ASPE Research Notes

INFORMATION FOR DECISION MAKERS
FOCUS ON: Disability/Long-Term Care Issued February 1995

Population Estimates of Disability and Long-Term Care

PDF Version: http://aspe.hhs.gov/daltcp/reports/1995/rn11.pdf (5 PDF pages)

Basic report
Licensed Board and Care Homes: Preliminary

Licensed Board and Care Homes: Preliminary Findings from the 1991 National Health Provider Inventory

U.S. Department of Health and Human Services Licensed Board and Care Homes: Preliminary Findings From the 1991 National Health Provider Inventory Robert F. Clark, DPA, and Joan Turek-Brezina, PhDU.S. Department of Health and Human Services Catharine W. Chu, MSPH, and Catherine Hawes, PhDResearch Triangle Institute April 11,
  • licbchom.pdf
    export-csvPDF

Pages

Form Approved OMB# 0990-0379 Exp. Date 9/30/2020